# Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

> **NCT00377065** · — · APPROVED_FOR_MARKETING · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** raltegravir

## Key facts

- **NCT ID:** NCT00377065
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2016-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00377065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00377065, "Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00377065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*